Near-Term Milestones
Clinical Programs
- Expected to begin Phase 3 alfimeprase trials in H1 ‘04
- Full publication of Phase 1 alfimeprase data in medical journal
- Presentation of Phase 1 alfimeprase data at the AIM Symposium
- Complete analysis of 50 secreted protein genes in Kirin collaboration
- Identify additional clinical candidates from Nuvelo genes
Secure strategic partners for antibody target and secreted protein programs
Successfully divest Variagenics and Callida assets